The 4th Congress on Controversies in Thrombosis and Hemostasis (CiTH) 2017 is dedicated to unresolved clinical, therapeutic dilemmas and clinical solutions related to Thrombosis and Hemostasis, including:
- Bleeding disorders
- The role of thrombopoietics in ITP
- Plasma derived vs. recombinant factor VIII concentrate
- Replacement therapy before surgery of factor XI & factor VII deficient patient
- Thrombotic disorders & antithrombotics
- Role of thrombophilia in gestation complication
- Thrombophilia screen
- Warfarin in the next 10 years
- Heparins in the next 10 years
- Direct thrombin inhibitors and factor Xa inhibitors
- Direct thrombin inhibitors and factor Xa inhibitors
- New antiplatelet agents
- Should we monitor anti platelet therapy
- The role of catheter guided thrombolysis in DVT
- Pharmacogenomics
- Primary prevention of coronary heart disease by ASA
- Extended VTE prophylaxis in medically ill patients
- Pediatrics
- Is there a role for primary antocoagulants prolphylaxis in children with ALL
- Should infants with perinatal thrombosis be screened for thrombophilia and treated by antocoagulants
- Should we screen children for coagulopathies prior to surgery?
- Prophylaxis for children with hemophilia should start early or after joint bleed? Is low dose regimen preferable to standard dose?
